News Sentiment

BLTE sentiment intelligence

Belite Bio Inc ADR news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 52 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 149.33 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 44

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+1.8% over one week, +8.1% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

Market Reaction

Balanced read

63/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction 1.8% Price digesting
Trend fit Trend inactive 8.1% over four weeks
Fair value 96.1% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 36
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 44
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
Stock Titan 7
TradingView 7
Investing.com 4
Sahm 4
GlobeNewswire 3
markets.businessinsider.com 2
Moomoo 2

Event Lens

What the news is about

Classified themes
Market update 25
Earnings 20
Analyst action 4
Regulatory and legal 1
Capital return 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 52
markets.businessinsider.com Direct company coverage

Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

Belite Bio, Inc. (NASDAQ: BLTE) announced its participation in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on July 22, 2026, at 3:00 pm ET. The clinical-stage drug development company focuses on novel therapeutics for degenerative retinal diseases like Stargar

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 13:16
Source
markets.businessinsider.com
Stock Titan Direct company coverage

Belite Bio's July 22 Ophthalmology Panel Will Be Online

Belite Bio (NASDAQ: BLTE) announced its participation in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on Wednesday, July 22, 2026, at 3:00 pm ET. The clinical-stage drug development company will join a panel discussion, and a live webcast with a 90-day replay w

Tone
Positive 63/100
Event
Market update
Published
15 Jul 2026 12:13
Source
Stock Titan
Sahm Direct company coverage

How Phase 3 DRAGON Trial Data Showcases At Major Conferences At Belite Bio (BLTE) Has Changed Its Investment Story

Belite Bio's Phase 3 DRAGON trial data for tinlarebant in Stargardt disease has been selected for oral presentations at major conferences, which will provide external experts a platform to scrutinize and contextualize the results, potentially shaping perceptions of the program’s

Tone
Positive 66/100
Event
Earnings
Published
08 Jul 2026 00:40
Source
Sahm
Sahm Direct company coverage

Belite Bio (BLTE) After New Phase 3 Data News And The Case For Fair Value

Belite Bio (BLTE) is gaining attention due to upcoming Phase 3 clinical trial results for its drug candidate, Tinlarebant. Despite recent share price volatility, the stock remains undervalued according to analyst targets and intrinsic estimates, with a fair value projected at $21

Tone
Positive 71/100
Event
Earnings
Published
07 Jul 2026 13:41
Source
Sahm
markets.businessinsider.com Direct company coverage

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

Belite Bio, Inc. (NASDAQ: BLTE) announced that data on its lead therapeutic candidate, tinlarebant, will be presented at two upcoming medical conferences: the 63rd Annual Symposium of the International Society for Clinical Electrophysiology of Vision (ISCEV) and the American Soci

Tone
Positive 72/100
Event
Market update
Published
07 Jul 2026 00:13
Source
markets.businessinsider.com
Market source Direct company coverage

Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium

Belite Bio, a clinical-stage drug development company, announced its participation in the Piper Sandler Virtual Ophthalmology Investor Symposium on July 9, 2026. The company will present in a fireside chat to discuss its progress in developing novel therapeutics for degenerative

Tone
Positive 64/100
Event
Market update
Published
07 Jul 2026 00:13
Source
Market source
Quiver Quantitative Direct company coverage

Belite Bio Announces Tinlarebant Phase 3 DRAGON Study Results to Be Presented at ISCEV 2026 and ASRS 2026 Meetings

Belite Bio will present data from its Phase 3 DRAGON study of tinlarebant for Stargardt Disease at the ISCEV and ASRS meetings in July 2026. The oral therapy aims to reduce harmful vitamin A-based toxins in the retina and has received Breakthrough Therapy, Fast Track, and Orphan

Tone
Positive 73/100
Event
Earnings
Published
06 Jul 2026 11:40
Source
Quiver Quantitative
Stock Titan Direct company coverage

Belite Bio to join Piper Sandler's virtual eye-disease investor event

Belite Bio (NASDAQ: BLTE) will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Investor Symposium on July 9, 2026, at 12:30 pm ET. The company, which specializes in therapies for degenerative retinal diseases, will have the webcast available for 90 days

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 11:40
Source
Stock Titan
Stock Traders Daily Direct company coverage

Responsive Playbooks and the BLTE Inflection

This article analyzes Belite Bio Inc (NASDAQ: BLTE), noting weak near-term sentiment but strong mid and long-term signals. It provides AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for s

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 05:40
Source
Stock Traders Daily
Moomoo Direct company coverage

Belite Bio | SCHEDULE 13G/A: Others

This document is a SCHEDULE 13G/A filing by others for Belite Bio. It signifies an amendment to a previous Schedule 13G filing, reflecting updated ownership information.

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 10:12
Source
Moomoo
TradingView Direct company coverage

Price to earnings forward of Belite Bio, Inc – NASDAQ:BLTE

This page provides information regarding the price to earnings forward of Belite Bio, Inc (NASDAQ: BLTE). It lists the company's stock market details from Nasdaq and indicates that the market is currently closed with no trades. The core content is limited to a table showing the "

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 22:10
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Belite Bio, Inc. ADR – FWB:D01

This page from TradingView provides financial information for Belite Bio, Inc. ADR (FWB:D01), specifically focusing on its forward price-to-earnings ratio. The article indicates the market was closed with no trades at the time of viewing. It details the company's financial overvi

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 17:09
Source
TradingView
TradingView Direct company coverage

Price to book forward of Belite Bio, Inc – NASDAQ:BLTE

This page from TradingView provides financial information for Belite Bio, Inc (BLTE) on the Nasdaq Stock Market. It specifically highlights the "Price to book forward" metric for the company. The content appears to be a financial data presentation page rather than a traditional a

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 13:10
Source
TradingView
TradingView Direct company coverage

Belite Bio, Inc. ADR Actuals & Estimates (NASDAQ:BLTE)

This page on TradingView provides a comprehensive overview of Belite Bio, Inc. ADR (NASDAQ:BLTE) financial actuals and analyst estimates. It allows users to explore reported financial data across income statements, balance sheets, cash flow statements, and valuation metrics. The

Tone
Neutral 50/100
Event
Analyst action
Published
26 Jun 2026 10:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Belite Bio, Inc – NASDAQ:BLTE

This article provides the enterprise value to revenue (forward) for Belite Bio, Inc (NASDAQ: BLTE). It displays the financial metric without further descriptive text or analysis, indicating it's likely a data point from a financial platform. The information is presented within th

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 01:10
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Belite Bio, Inc – BOATS:BLTE

This page displays the "Price to sales forward" financial metric for Belite Bio, Inc (BLTE) on the Blue Ocean Alternative Trade System (BOATS) via TradingView. The article indicates that the market is currently closed, showing no trades. It provides a snapshot of the financial da

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 15:41
Source
TradingView
Sahm Direct company coverage

Belite Bio (BLTE) After Its FDA Filing, Does The Stock Still Look Undervalued

Belite Bio (BLTE) recently completed a New Drug Application submission to the FDA for tinlarebant, a potential treatment for Stargardt disease. Despite a mixed trading performance and insider share sales, the stock is currently assessed as 28.7% undervalued with a fair value of $

Tone
Positive 66/100
Event
Market update
Published
25 Jun 2026 09:39
Source
Sahm
Investing.com South Africa Direct company coverage

Form 4 Belite Bio Inc ADR For: 22 June By Investing.com

This article from Investing.com reports on a Form 4 filing for Belite Bio Inc ADR on June 22. It is a brief announcement about a regulatory filing, characteristic of financial news updates. The article includes the stock symbol BLTE and its performance.

Tone
Neutral 50/100
Event
Regulatory and legal
Published
22 Jun 2026 18:39
Source
Investing.com South Africa
Stock Titan Direct company coverage

Bioptima Ltd. tied to Belite Bio (BLTE) CMO sells 10,000 ADSs in open market

Bioptima Ltd., an entity linked to Belite Bio's Chief Medical Officer Hendrik Peter Scholl, sold 10,000 American depositary shares (ADSs) in open market transactions on June 18, 2026. The sales, executed in multiple blocks at prices ranging from $143.90 to $147.11 per ADS, result

Tone
Negative 28/100
Event
Market update
Published
22 Jun 2026 09:40
Source
Stock Titan
Sahm Direct company coverage

Why Belite Bio (BLTE) Is Up 5.8% After Completing FDA NDA Submission For Tinlarebant

Belite Bio's stock rose 5.8% after completing its New Drug Application (NDA) submission to the FDA for tinlarebant, a treatment for Stargardt disease type 1. The drug has Breakthrough Therapy Designation, indicating potential for expedited review, and is projected to generate sig

Tone
Positive 71/100
Event
Market update
Published
22 Jun 2026 06:40
Source
Sahm
Stock Titan Direct company coverage

Dr. Hendrick Scholl sells 10,000 ADS as Form 144 filed (NASDAQ: BLTE)

Dr. Hendrick P. Scholl has filed a Form 144, notifying the SEC of his intent to sell 10,000 American Depositary Shares (ADS) of Belite Bio, Inc. (NASDAQ: BLTE) on June 16, 2026. The filing also details vested Restricted Stock Units (RSUs) of 2,500 ADS and 7,500 ADS, which vested

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 20:15
Source
Stock Titan
TradingKey Direct company coverage

Belite Bio Inc (BLTE) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for Belite Bio Inc (BLTE), detailing analyst ratings, target prices, and historical and projected EPS. Based on 8 analysts, the stock has a "Buy" consensus, with a target price of USD 210.50. The piece also includes a peer comparison and

Tone
Positive 72/100
Event
Earnings
Published
18 Jun 2026 00:40
Source
TradingKey
TradingKey Direct company coverage

Belite Bio Inc (BLTE) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Belite Bio Inc's (BLTE) dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and reports no data regarding past stock splits. The piece presents current stock performance data

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 13:39
Source
TradingKey